Literature DB >> 18024013

Common variants of DNA repair genes and malignant melanoma.

T Debniak1, R J Scott, B Górski, C Cybulski, T van de Wetering, P Serrano-Fernandez, T Huzarski, T Byrski, L Nagay, B Debniak, E Kowalska, A Jakubowska, J Gronwald, D Wokolorczyk, R Maleszka, J Kładny, J Lubinski.   

Abstract

In the current study, we evaluated the possible associations of seven common variants of the DNA repair and cell cycle control genes BRCA2 and CHEK2 with malignant melanoma (MM). We genotyped 630 unselected MM patients and over 3700 controls (newborns, age- and sex-matched healthy adults with negative cancer family histories, and the adults selected at random by family doctors) for the prevalence of three common variants of the BRCA2 (T1915M, N991D and N372H) and four common variants of the CHEK2 (1100delC, VS2+1G --> A, I157T and del5395). Our study strongly suggests that the common variant of the BRCA2 gene -- the N991D variant is associated with malignant melanoma risk (OR=1.8, p=0.002 after Bonferroni correction). Patients homozygote for the N991D variant were present in 0.32% of cases and only 0.13% of controls. The other variants studied were not over-represented among MM patients when compared to the general population. In conclusion, we report an increased melanoma risk among carriers of the N991D change of the BRCA2 and no association of the CHEK2 changes with malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024013     DOI: 10.1016/j.ejca.2007.10.006

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer.

Authors:  Petra E A Huijts; Antoinette Hollestelle; Brunilda Balliu; Jeanine J Houwing-Duistermaat; Caro M Meijers; Jannet C Blom; Bahar Ozturk; Elly M M Krol-Warmerdam; Juul Wijnen; Els M J J Berns; John W M Martens; Caroline Seynaeve; Lambertus A Kiemeney; Henricus F van der Heijden; Rob A E M Tollenaar; Peter Devilee; Christi J van Asperen
Journal:  Eur J Hum Genet       Date:  2013-05-08       Impact factor: 4.246

Review 2.  Skin cancer risk in BRCA1/2 mutation carriers.

Authors:  P V Gumaste; L A Penn; R M Cymerman; T Kirchhoff; D Polsky; B McLellan
Journal:  Br J Dermatol       Date:  2015-04-29       Impact factor: 9.302

3.  MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.

Authors:  J C Hassel; A Sucker; L Edler; H Kurzen; I Moll; C Stresemann; K Spieth; C Mauch; K Rass; R Dummer; D Schadendorf
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

4.  Genome-wide association study identifies three loci associated with melanoma risk.

Authors:  D Timothy Bishop; Florence Demenais; Mark M Iles; Mark Harland; John C Taylor; Eve Corda; Juliette Randerson-Moor; Joanne F Aitken; Marie-Francoise Avril; Esther Azizi; Bert Bakker; Giovanna Bianchi-Scarrà; Brigitte Bressac-de Paillerets; Donato Calista; Lisa A Cannon-Albright; Thomas Chin-A-Woeng; Tadeusz Debniak; Gilli Galore-Haskel; Paola Ghiorzo; Ivo Gut; Johan Hansson; Marko Hocevar; Veronica Höiom; John L Hopper; Christian Ingvar; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Jan Lubiński; Rona Mackie; Josep Malvehy; Graham J Mann; Nicholas G Martin; Grant W Montgomery; Frans A van Nieuwpoort; Srdjan Novakovic; Håkan Olsson; Susana Puig; Marjan Weiss; Wilbert van Workum; Diana Zelenika; Kevin M Brown; Alisa M Goldstein; Elizabeth M Gillanders; Anne Boland; Pilar Galan; David E Elder; Nelleke A Gruis; Nicholas K Hayward; G Mark Lathrop; Jennifer H Barrett; Julia A Newton Bishop
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

Review 5.  The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.

Authors:  Arindam Paul; Soumen Paul
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01

6.  The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN).

Authors:  Kathrin Scheckenbach; Galatia Papadopoulou; Thomas K Hoffmann; Adam Chaker; Henning Bier; Jörg Schipper; Vera Balz; Martin Wagenmann
Journal:  J Negat Results Biomed       Date:  2010-12-25

7.  Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.

Authors:  O Bougie; J I Weberpals
Journal:  Int J Surg Oncol       Date:  2011-08-08

8.  Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.

Authors:  Barbara Peric; Petra Cerkovnik; Srdjan Novakovic; Janez Zgajnar; Nikola Besic; Marko Hocevar
Journal:  BMC Med Genet       Date:  2008-09-19       Impact factor: 2.103

9.  Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.

Authors:  Milena Casula; Antonio Muggiano; Antonio Cossu; Mario Budroni; Corrado Caracò; Paolo A Ascierto; Elena Pagani; Ignazio Stanganelli; Sergio Canzanella; Mariacristina Sini; Grazia Palomba; Giuseppe Palmieri
Journal:  BMC Cancer       Date:  2009-10-03       Impact factor: 4.430

10.  Principles of genetic predisposition to malignancies.

Authors:  Tadeusz Debniak; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.